Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$164.99 USD
-2.37 (-1.42%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $164.96 -0.03 (-0.02%) 7:22 PM ET
4-Sell of 5 4
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$164.99 USD
-2.37 (-1.42%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $164.96 -0.03 (-0.02%) 7:22 PM ET
4-Sell of 5 4
C Value F Growth F Momentum F VGM
Zacks News
Retail Sales Hotter at +0.7%; JNJ, BAC, GS All Beat in Q3
by Mark Vickery
Retail Sales infer a consumer willing to spend, and the outlook for Q3 GDP is likely up somewhat on this news.
Johnson & Johnson (JNJ) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Johnson & Johnson (JNJ) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Johnson & Johnson (JNJ) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 5.56% and 1.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Markets Pop on Bargain Hunting, Stronger Economy
by Mark Vickery
The small-cap Russell 2000, still under water over the past month, led the way higher today.
Will Big Stocks Make Big Headlines? Global Week Ahead
by John Blank
This trading week might offer some reassurance -- that both households and businesses are holding up -- in an uncertain macro environment.
Wall Street Waits for Big Earnings Results
by Zacks Equity Research
Wall Street Waits for Big Earnings Results.
Empire State Less Bad than Expected; SCHW Mixed in Q3
by Mark Vickery
We've only seen four months in positive territory on Empire State manufacturing year to date, the highest being +10.8 in April.
Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DGRO
Eli Lilly's (LLY) Mirikizumab Meets Crohn's Disease Study Goals
by Zacks Equity Research
Based on this data, Eli Lilly (LLY) will initiate regulatory submissions worldwide next year seeking regulatory approval for mirikizumab in Crohn's disease.
J&J (JNJ) to Report Q3 Earnings, Its First After Unit Spin-Off
by Zacks Equity Research
J&J's (JNJ) third-quarter results are the first quarterly update for the new company after the Consumer Health spin-off.
Pharma Stock Roundup: LLY Meets IBD Study Goal, PFE, MRK Give Cancer Pipeline Updates
by Kinjel Shah
Eli Lilly's (LLY) mirikizumab meets the main goals in a Crohn's disease study. PFE, MRK and JNJ provide updates on cancer drugs in their pipeline.
Dow ETF in Focus Ahead of Q3 Earnings
by Sweta Killa
With some of the blue-chip companies having reasonable chances of coming up with an earnings surprise, investors should closely monitor the movement of the Dow ETF and grab any opportunity that arises from a surge in any of the 30 stocks.
Earnings Preview: Johnson & Johnson (JNJ) Q3 Earnings Expected to Decline
by Zacks Equity Research
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for HDV
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VYM
J&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLC
by Zacks Equity Research
J&J (JNJ) files an application in Europe seeking expanded approval for Rybrevant as a first-line combination treatment in patients with advanced or metastatic EGFR exon 20 insertion mutation-positive NSCLC.
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Sanofi (SNY) Inks Deal With J&J to Develop E. coli Vaccine
by Zacks Equity Research
Per the terms of the deal, Sanofi (SNY) and J&J will co-fund current and future R&D costs to develop a potential first-in-class vaccine against extraintestinal pathogenic E. coli.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $155.15 in the latest trading session, marking a -0.39% move from the prior day.
J&J's (JNJ) Rybrevant Combo Meets Primary Goal in NSCLC Study
by Zacks Equity Research
J&J (JNJ) meets the primary goal in the late-stage study of the combination therapy of Rybrevant and lazertinib against Tagrisso for EGFR-mutated first-line NSCLC.
The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J
by Zacks Equity Research
AbbVie, Lilly, Sanofi, Merck and J&J are included in this Analyst Blog.
Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK's Drugs
by Kinjel Shah
The European Commission approves AbbVie's (ABBV) Tepkinly (epcoritamab) for DLBCL. FDA approves Lilly's (LLY) Jardiance for chronic kidney disease.